Abeona therapeutics reports second quarter 2023 financial results

On track for biologics license application (bla) submission in third quarter of 2023 proceeds from $25 million registered direct offering in july allow initiation of pre-commercial launch activities for eb-101 cash on hand plus proceeds from registered direct offering projected to fund operations into the fourth quarter of 2024 cleveland, aug. 08, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives. “abeona is at a pivotal moment in our history as we are busy finalizing and planning to soon submit the bla for eb-101 for the treatment of recessive dystrophic epidermolysis bullosa,” said vish seshadri, chief executive officer of abeona.
ABEO Ratings Summary
ABEO Quant Ranking